Q3 FY2026 · ended Sep 30, 2026 · Revenue $12.70M, +21.5% YoY · Filed Nov 5, 2026
Alpha Teknova, Inc. (TKNO) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $12.7 million and a net loss of $3.5 million. Free cash flow was -$1.4 million. As of Sep 30, 2026 it held $16.6 million in cash and investments and $27.0 million in total debt.
Revenue
$12.70M
+21.5% vs year-ago quarter
Net income
$-3.49M
+18.6% vs year-ago quarter
Operating cash flow
$-1.28M
+35.5% vs year-ago quarter
Free cash flow
$-1.40M
+40.9% vs year-ago quarter
EPS
$-0.06
+25.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
62.90M
+17.5% vs year-ago quarter
Net cash
$-10.43M
Q3 FY2026
Operating margin
-32.7%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- TKNO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hollister, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1850902
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $12.7M | $12.2M | $11.1M | $10.0M | $10.5M |
| Operating income | -$3.2M | -$2.9M | -$4.3M | -$4.6M | -$4.0M |
| Net income | -$3.5M | -$3.2M | -$4.6M | -$4.8M | -$4.3M |
| Diluted EPS | -$0.06 | -$0.06 | -$0.08 | -$0.09 | -$0.08 |
| Operating cash flow | -$1.3M | -$471,000 | -$3.4M | -$462,000 | -$2.0M |
| Free cash flow | -$1.4M | -$596,000 | -$3.6M | -$810,000 | -$2.4M |
| Total assets | $94.7M | $95.9M | $98.7M | $103.6M | $107.6M |
| Total liabilities | $34.9M | $33.3M | $33.7M | $34.8M | $35.0M |
| Stockholders' equity | $59.8M | $62.6M | $64.9M | $68.8M | $72.7M |
| Cash and investments | $16.6M | $17.4M | $17.8M | $21.3M | $22.1M |
| Total debt | $27.0M | $27.4M | $27.8M | $28.3M | $29.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 1, 2026 | May 27, 2026 |
All 222 Alpha Teknova, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.